Literature DB >> 3495472

Improved specificity of the PABA test with p-aminosalicylic acid (PAS).

F J Hoek, F A van den Bergh, J T Klein Elhorst, J L Meijer, E Timmer, G N Tytgat.   

Abstract

Until now use of the PABA test together with [14C] PABA to calculate the PABA excretion index has probably been the best adaptation suggested to enhance the specificity of this non-invasive pancreatic function test. Drawbacks of the method are the application of radioactivity, the fact that children, pregnant women, and patients with renal insufficiency have to be excluded from the test, and the possible interference of drugs and isotopes. We propose simultaneous administration of p-aminosalicylic acid (PAS) in the PABA test and quantification of the urinary PABA and PAS excretion with liquid chromatography. Urinary PABA and PAS excretion in six hours are comparable (69.5 +/- 8.4% and 65.6 +/- 18.4% respectively in five healthy volunteers). Application of the PABA/PAS ratio was compared with the urinary PABA excretion in 21 normal controls, 38 patients with pancreatic disease, and 42 patients without pancreatic pathology. The PABA/PAS ratio and the per cent PABA excretion correlated very well in pancreatic patients: (PABA/PAS ratio) = 0.0149 (% PABA) + 0.052 (r = 0.902). Use of the PABA/PAS ratio enhanced the specificity of the test from 76 to 89%.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3495472      PMCID: PMC1432836          DOI: 10.1136/gut.28.4.468

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  12 in total

1.  Bioavailability of aminosalicylic acid and its various salts in humans. 3. Absorption from tablets.

Authors:  S H Wan; P J Pentikainen; D L Azarnoff
Journal:  J Pharm Sci       Date:  1974-05       Impact factor: 3.534

2.  Observations on the BT PABA/14C-PABA tubeless test of pancreatic function.

Authors:  J M Braganza; G H Kay; V A Tetlow; K J Herman
Journal:  Clin Chim Acta       Date:  1983-06-15       Impact factor: 3.786

3.  Optimum dose of bentiromide.

Authors:  A R Imondi
Journal:  Dig Dis Sci       Date:  1983-09       Impact factor: 3.199

4.  In vitro and in vivo analysis of the PABA test compared with the Lundh test--influence of intraluminal pH.

Authors:  F J Hoek; G T Sanders; A Teunen; G N Tijtgat
Journal:  Gut       Date:  1981-01       Impact factor: 23.059

Review 5.  Exocrine pancreatic function tests.

Authors:  P G Lankisch
Journal:  Gut       Date:  1982-09       Impact factor: 23.059

6.  [The determination of p-aminobenzoic acid in urine with Fluram for performing pancreatic function tests with bentiromide].

Authors:  H G Eisenwiener; F Morger; W Lergier; D Gillessen
Journal:  J Clin Chem Clin Biochem       Date:  1982-08

7.  Improved diagnostic accuracy of a modified oral pancreatic function test.

Authors:  C J Mitchell; C S Humphrey; A W Bullen; J Kelleher; M S Losowsky
Journal:  Scand J Gastroenterol       Date:  1979       Impact factor: 2.423

8.  Urinary p-aminobenzoic acid determined in the pancreatic function test by liquid chromatography, with electrochemical detection.

Authors:  S Ito; K Maruta; Y Imai; T Kato; M Ito; S Nakajima; K Fujita; T Kurahashi
Journal:  Clin Chem       Date:  1982-02       Impact factor: 8.327

9.  Relationship between PABA and Lundh tests: lack of influence of duodenal pH in vivo.

Authors:  G H Kay; V A Tetlow; J M Braganza
Journal:  Clin Chim Acta       Date:  1983-02-28       Impact factor: 3.786

10.  Preliminary evaluation of a single-day tubeless test of pancreatic function.

Authors:  C J Mitchell; H P Field; F G Simpson; A Parkin; J Kelleher; M S Losowsky
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-30
View more
  2 in total

1.  Do we still need to measure faecal fat?

Authors:  G K Holmes; P G Hill
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-04

2.  Assessment of gastrointestinal function and response to megesterol acetate in subjects with gastrointestinal cancers and weight loss.

Authors:  John Deutsch; J Fred Kolhouse
Journal:  Support Care Cancer       Date:  2004-04-03       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.